Giralt, S.A., Mangan, K.F., Maziarz, R.T., Bubalo, J.S., Beveridge, R., Hurd, D.D., … Schuster, M.W. (2011). Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology, 22, 939–946.
The study was conducted in an outpatient setting at Memorial Sloan Kettering Cancer Center in New York.
All patients were in active treatment.
This was a double-blind, randomized pilot study.
A multiple-dose schedule of palonosetron as used here was not associated with any increase in adverse events. No definitive conclusions can be drawn regarding the benefit of multiple-day administration of palonosetron.
Further evaluation of multiple-day schedules of palonosetron are warranted. Even with multiple dosing, 80% of these patients had episodes of emesis or required rescue medication, pointing to the continuing challenge to determine more effective methods and combinations to meet this patient need.